ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc. (ACHFF)
About ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc. (ACHFF)
Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.